Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Companies Coronavirus COVID-19 Research & Development

COVID-19 Lessons: Experts Predict Shift Toward Intermittent Hemodialysis In ICUs

  • Analysis

Executive Summary

The pandemic may accelerate a move toward versatile, single-solution renal replacement therapy in intensive care.

You may also be interested in...



CMS Final Kidney Disease Treatment Model To Encourage More Home Dialysis

The US Medicare agency introduced a new end-stage renal disease treatment model on Friday to incentivize use of home dialysis.

COVID-19 Continues To Drive Demand For Baxter’s Acute Therapies Portfolio

Demand for Baxter's acute therapy products helped offset declines across its advanced surgery, pharmaceuticals and medication-delivery businesses in the second quarter.

FDA Clears Medtronic’s CRRT System For Pediatric Kidney Disease

The de novo clearance makes the Carpediem system the first commercially available system indicated for continuous renal replacement therapy in pediatric patients.

Table

View full table

Topics

Related Companies

Tags:
Companies Coronavirus COVID-19 Research & Development
Latest Headlines

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion

Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations

Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application

See All
UsernamePublicRestriction

Register

MT142819

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By